

3rd Aug 2020

To,

Dr. Suhel Parvez,
Jamia Hamdard University
New Delhi

From,

Ritu Kothari,
Colorbar Cosmetics Pvt Ltd
New Delhi

Sub: Request for project at Jamia Hamdard

Dear Dr. Suhel,

This letter is to request you on behalf of Jamia Hamdard University to support us in the lab experiment and investigation with regards to our in-house project on given Colorbar skin care products.

Regards,

Ritu Kothari



HempCann®

SOLUTIONS

Sealing Lives Holistically

Ref: HCS/CP/SEP/2019

To

Dr. Bibhu Prasad Panda

Associate Professor

Department of Pharmacognosy and Phytochemistry

Jamia Hamdard

Consultancy
Project

Annex-9

Date: 17.09.2019

Sub: Letter of confirmation to undertake the consultancy project

Dear Sir,


Thanks for considering the proposal and approved by Office of Advisor (Research), Jamia Hamdard for undertaking the consultancy project "Method development for quantification of Vijaya Leaf extract by UPLC-MS/MS for evaluation of its pharmacokinetics and toxicokinetic profile on Wistar Albino rats" with a cost of Rs. 6,05,000/- . Please find below the terms and conditions for conducting this project:

1. Duration of project is 6 months and starting date would be after receiving the sample and the first payment.
2. Total payment will be done in 6 installments.
3. PI has to submit the detailed Objective of the Experiment, Study protocol and the observations.
4. A monthly progress report has to be submitted at the end of every 30 days.
5. HempCann Solutions has the equal ownership of any finding and Intellectual properties (IP) as the outcome of this research.
6. PI can go for publication with the data from this research after getting the consent from HempCann Solutions. And HempCann representatives should be a co-author for the paper.
7. HempCann has all the right to use the results for marketing purposes.
8. If in any case, the objective of the project needs a further extension to find the results, PI should have to complete it without adding any extra cost to the budget.
9. After completion of project, PI should disclose all the expenses done on behalf and submit the detailed report to HempCann Solutions as the closure report of the project.

Looking forward to hearing from you soon.

With best regards,

For HempCann Solutions Pvt Ltd.



Managing Director

Teek Transfer

ANX - 11



北京泛球生物科技有限公司

Global Biologicals Co., Ltd

Rm 510 Unit 2 No.99 Yuexiu Road Haidian
District, Beijing 100096 China
Tel: +86 10 62981422 Fax: +86 10 62981422
Email: info@globalbiologicals.com

Date: 09/05/2017


CERTIFICATE OF APPRECIATION FOR
ASTAXANTHIN TECHNOLOGY TRANSFER

We are happy to acknowledge Dr Bibhu Prasad Panda, Sr. Assistant Professor, School of Pharmaceutical Sciences and Research, Jamia Hamdard, New Delhi for his research on the Natural Astaxanthin Production through fermentation process.

This technology is promising for commercialization as it yields high Astaxanthin content in low cost fermentation media.

We are interested in the technology and the process from Dr Bibhu Prasad Panda. It will initiate a long term co-operation between Jamia Hamdard, New Delhi, India and Beijing Global Biologicals Co. Ltd. Beijing, China ultimately leading to form a bridge for better Indo-China joint scientific research and relationship.

The present technology will certainly help in reducing the production cost of natural Astaxanthin, which currently is very high as well as will help for the betterment of the society and mankind.

With regards,

Dr Fujun Wang
President
Beijing Global Biologicals Co., Ltd. Beijing,
People Republic of China.



JAMIA HAMDARD

Hamdard Nagar, New Delhi-110062
Phone : 26059688

S.No.: 125907

Date

R. No.

RECEIPT VOUCHER

Account	Amount (Rs.)
1958	2015-2017
Transfer of Rs. 12,77,015.28	12,77,015.28
BY BANK	
AMOUNT CREDITED BY BO BRAC ON 12	
SEP 1958 BRAC BRAC BRAC BRAC	
On Account of	
to be credited to the account of	
Treasurer of Hamdard Twenty Eight base City	12,77,015.28
Amount (in words)	
	Rs.

Cashier



JAMIA HAMDARD

(Hamdard University)

(Declared as Deemed-to-be University under Section 3 of
the UGC Act, 1956 vide Notification No. F.9-18/85-U.3
dated 10.5.1989 of the Government of India)

Accredited by NAAC in 'A' Category

Phone : 011 2605 9688 (12 Lines)
Fax : 00-91-11-26059663
E-mail : inquiry@jamiahamdard.edu
Website : www.jamiahamdard.edu

HAMDARD NAGAR
NEW DELHI - 110062

May 9, 2017

INVOICE


M/s Beijing Global Biological Co. Ltd.
Room No.510, Unit-2 Tongsha Gongyuan 99
Building No.99, Yuexiu Road,
Haidian District
Beijing -100096, China

Technology Transfer of
Astaxanthin Fermentation
Process (First Part)

US\$ 20,000/-

US\$ 20,000/-

US Dollar twenty thousand only.


FINANCE OFFICER
Finance Officer
Jamia Hamdard
(Deemed University)
Hamdard Nagar
New Delhi-110062

Bank Details

Pay to Bank of India, New York ABA 026005458
(BKIDUS33) for credit to A/c No.0003325000 of
BKIDINBB for further credit to BKIDINBBANPL
Quoting ref. No. Jamia Hamdard current A/c No.
601820100120001.



“QUALITY CONTROL ASSESSMENT OF MANJISH GLOW ELIXIR OIL”



Transformative
Learning Solutions (P) Ltd

Work undertaken at

Bioactive natural product laboratory, SPER

Jamia Hamdard, New Delhi-110062

Submitted to

Transformative Learning Solutions (TLS) PVT. LTD.,

New Delhi



**“QUALITY CONTROL ASSESSMENT OF AMBHRING
AGE EMBRACE REVITALIZER OIL”**



Transformative
Learning Solutions (P) Ltd

Work undertaken at

Bioactive natural product laboratory, SPER

Jamia Hamdard, New Delhi-110062

Submitted to

Transformative Learning Solutions (TLS) PVT. LTD.,

New Delhi



**“QUALITY CONTROL ASSESSMENT OF KESARADI
OIL”**



Transformative
Learning Solutions (P) Ltd

Work undertaken at
Bioactive natural product laboratory, SPER
Jamia Hamdard, New Delhi-110062
Submitted to
Transformative Learning Solutions (TLS) PVT. LTD.,
New Delhi



**“QUALITY CONTROL ASSESSMENT OF KANSA
OIL”**



Transformative
Learning Solutions (P) Ltd

Work undertaken at

Bioactive natural product laboratory, SPER

Jamia Hamdard, New Delhi-110062

Submitted to

Transformative Learning Solutions (TLS) PVT. LTD.,

New Delhi

DOLPHIN

CONSULTANCY PROJECT REPORT



**FINAL REPORT OF INDUSTRY BASED
CONSULTANCY PROJECT**

**QUALITY CONTROL EVALUATION OF CARICA
PAPAYA LEAF EXTRACT AND JUICE**



SUBMITTED BY

DR. SAYEED AHMAD

In charge, Bioactive Natural Product Laboratory
Department of Pharmacognosy and Phytochemistry
School of Pharmaceutical Education and Research
Jamia Hamdard, New Delhi 110062

SUBMITTED TO

Dolphin International Pvt Ltd
B-210, Okhla Industrial Area, Phase 1, New Delhi-110020

21/09/2018

Bioactive Natural Product Laboratory

Department of Pharmacognosy and Phytochemistry
School of Pharmaceutical Education and Research

Date: 24/09/2018

MR GAURAV
S/O: DAYANAD SINGH
DHAULANA, DIST: HAPUR
PIN 245301
Mobile: +91-9760477960
E-mail: GAUTAMGAURAV878@GMAIL.COM

SUBJECT: SELECTION AS SENIOR RESEARCH FELLOW (SRF PHARMACOGNOSY) UNDER INDUSTRY SPONSORED CONSULTANCY PROJECT

Dear MR GAURAV


The undersigned is pleased to inform you that as per the results of Selection Committee followed by approval from competent authority, you have been selected as a **Senior Research Fellow (SRF)** under **Industry sponsored (AIMIL PHARMACEUTICALS LTD.) consultancy project**. You will be paid a fellowship of Rs 25000/ month.

The appointment will be for an initial period of one year which is extendable for a maximum period of two years (keeping in view your performance) or the duration of the consultancy project whichever is earlier.

The other terms and conditions of your appointment will be the same as per the norms of the projects and Ph. D. bylaws of Jamia Hamdard. You are requested to join as soon as possible for execution of program.

Hoping to hear from you soon.

DR. SAYEED AHMAD
Incharge
Bioactive Natural Product Laboratory
Department of Pharmacognosy & Phytochemistry
School of Pharmaceutical Education & Research
Jamia Hamdard, Hamdard Nagar, New Delhi-62, India


24/09/2018
Dr. Sayeed Ahmad

In charge, Bioactive Natural Product Laboratory &
Co-ordinator: Dabur Research fellowship program
Department of Pharmacognosy and Phytochemistry
School of Pharmaceutical Education and Research
Jamia Hamdard, New Delhi -110062
E-mail: sahmad_jh@yahoo.co.in
Phone no. 011-26059688, Mobile: 9891374647




सत्यमेव जयते

INDIA NON JUDICIAL

Government of National Capital Territory of Delhi

e-Stamp

Certificate No.	: IN-DL41364372897595P
Certificate Issued Date	: 12-Oct-2017 09:57 AM
Account Reference	: IMPACC (IV)/ dl740303/ DELHI/ DL-DLH
Unique Doc. Reference	: SUBIN-DL74030384681387749851P
Purchased by	: REGISTRAR JAMIA HAMDARD
Description of Document	: Article 5 General Agreement
Property Description	: Not Applicable
Consideration Price (Rs.)	: 0 (Zero)
First Party	: REGISTRAR JAMIA HAMDARD
Second Party	: Not Applicable
Stamp Duty Paid By	: REGISTRAR JAMIA HAMDARD
Stamp Duty Amount(Rs.)	: 100 (One Hundred only)



.....Please write or type below this line.....

MEMORANDUM OF UNDERSTANDING

The Memorandum of understanding executed this 13th day of October, 2017 at New Delhi.

BETWEEN

Jamia Hamdard (Deemed University), Hamdard Nagar, New Delhi-110062, through its Registrar presently Prof. Ehsan Ahmad Khan, duly authorized to enter into and sign MOU on behalf of Jamia Hamdard (hereinafter referred to as 'JHU'), PARTY OF THE FIRST PART.

AND

Dabur India Limited, with its office at Sahibabad, Ghaziabad (U.P)-201010 through its Executive Director HR presently Mr. V. Krishnan duly authorized in this regards, (hereinafter referred to as 'DABUR'), PARTY OF THE SECOND PART.

The expressions of the Jamia Hamdard & DABUR shall, however, mean and include the institutions/Organization, their successors, appointee, assignees etc.

NOW THIS MEMORANDUM OF UNDERSTANDING WITNESSETH:

1. Dabur, will be a 'Research Collaborator' of Jamia Hamdard.
2. There will be collaboration between the medical/pharmacy and basic science Schools of Jamia Hamdard and the scientists of Dabur in the areas of joint interests.
3. This collaboration will extend the facilities of the two institutions/labs for the complementing joint research projects and to train each other's students /faculty to facilitate the overall research and training.
4. Dabur will provide the research fellowship (Dabur Research Fellowship) to one of the research scholar working in the field of Bioactive Natural Products at JHU who will be working on medicinal plants/ formulations as mutually decided by JHU and DABUR.
5. Dabur will pay ₹.3,60,000/- annually (including fellowship and contingency) to the research scholar during his/her entire course of work, up to maximum for the three years.
6. Research scholar will do the entire course of work and research in JHU and DABUR
7. The authentic plant material / product/ samples required by Scholar in Dabur Research Fellowship will be provided by Dabur as gift sample.
8. The Scientists working at DABUR will be acting as Co-Supervisor of Ph D Student registered under Dabur Research Fellowship, Dabur shall forward names of such scientists to JHU along with their CVs and list of publications
9. JHU and Dabur will independently cover the cost of research chemicals & other expenditure incurred in connection with the research collaboration.




EA Khan Registrar
Jamia Hamdard
(Deemed University)
Hamdard Nagar
New Delhi-110062



10. Dabur will provide short-term training to students and faculty members of the Jamia Hamdard in their areas of specialization on the request from the University.
11. Scientists of Dabur may be invited to deliver lectures in specific courses or seminars of JHU
12. IPR related issues shall be jointly shared by Dabur and JHU. The parties herein agree that DABUR shall have the first right of refusal for commercial utilization of the inventions, Derivatives, discovery or improvement made, conceived or acquired from the data utilized in such **Research Projects**.
13. The tenure of the MOU is for a period for three years commencing from its signing. This MOU may be amended / extended for specified duration by mutual consent in writing of both the parties.
14. This MOU may be terminated by either institution at any time provided that the terminating institution gives to other party written notice of intention to terminate at least six months prior to termination.
15. A joint committee shall be constituted to periodically review the progress of this MOU.
16. Any dispute arising out of this Memorandum of Understanding or in its enforcement the concerned parties to this MOU will resolve the same amicably. However, in case if the dispute remains unresolved it shall be referred to an arbitrator to be appointed by mutual consent of both the parties subject to Delhi jurisdiction. The decision of the arbitrator shall be final and binding upon the party concerned.

In witness whereof, the Registrar, Jamia Hamdard, and the Vice President, (R&D) Dabur India Limited, have hereinto signed this MOU on the day and year first above written.




 Mr. V. Krishnan
 Executive Director-HR
 Dabur India Limited
 22, Site IV, Sahibabad
 Ghaziabad-201010


 Prof. Ehsan A. Khan
 Registrar
 Jamia Hamdard
 Hamdard Nagar
 New delhi-110062

WITNESSES:

1. 
 (HIMANSHU BHATIA)
2. 
 [J.L.N. SASTRI]
 Head - Healthcare Research

WITNESSES:

1. 
 Dr. Sayeed Ahmed
2. 
 P. S. Kaminde
 Advisor (Research)

Statement of Expenditure/Utilization Certificate of CARS (DIPAS) project


(14th March 2016 till 31st January 2017)

1. Title of the project: Stability and Bioavailability studies on tablet DIP-G-411
2. Sanction letter No: Ref. No. ST/14/15/DIP-265/S&T
3. Total project cost: **Rs. 9,96,000/-**
4. Date of commencement of project: 14th March 2016
5. Statement of expenditure: 14 March 2016 – 31 January 2016
6. Name of the institution: **JAMIA HAMDARD**
7. Principal investigator: **DR. SAYEED AHMAD**
8. Head of account as given in the original sanction letter:
Initial / total advance = 5.0 lacs (28th January 2016) (Including wages, consumables and committed)
9. Total expenditure during the tenure: **Rs. 6,07,709.00 lacs** (Rs 158710.00 as wages, Rs 370483 as Miscellaneous contingency, consumables and 78516 already committed)
10. Excess of expenditure: 1,07,709.00 lac.

Certificate

Certified that out of **Rs. 5,00,000** of grant-in-aid sanctioned during the year 14 March 2015-31, January 2017 in favour of Jamia Hamdard under DIPAS Ref. No. ST/14/15/DIP-265/S&T, dated 28th January 2016, a sum of Rs. 6,07,709.00 has been utilized till 31 January 2017.

Signature of Principal Investigator With date	Signature of Finance Officer With date	Signature of Head of Institution With date
---	--	--


13/02/2017
Dr. SAYEED AHMAD
Incharge
Bioactive Natural Product Laboratory
Dept. of Pharmacognosy & Phytochemistry
Faculty of Pharmacy, Jamia Hamdard
Hamdard Nagar, New Delhi-110062, India


Finance Officer
Jamia Hamdard
(Deemed University)
Hamdard Nagar
New Delhi-110062



AIMIL

PHARMACEUTICALS (INDIA) LIMITED
MANUFACTURERS & EXPORTERS OF PHARMACEUTICALS PRODUCTS

An ISO 9001: 2008 Certified Company

Ref. No.: AIMIL/2019/PD/122

Dated: September 09, 2019

To,

Dr. Showkat R. Mir,
Associate Professor,
Phyto-pharmaceutical Research Laboratory,
Department of Pharmacognosy & Phytochemistry,
School of Pharmaceutical Education & Research,
Jamia Hamdard, New Delhi - 110062

Subject: Our acceptance to sponsor proposed Consultancy Project entitled "DEVELOPMENT OF CHROMATOGRAPHIC METHODS FOR THE ESTIMATION OF BIO-ACTIVE MARKERS IN MEMTONE & ITS SCREENING FOR EFFECT ON COGNITIVE FUNCTIONS" under your supervision as Principal Investigator.

Respected Sir,

Season's Greetings!

We refer to our discussions on the subject and subsequent proposal entitled as above, submitted to us for the purpose of sponsorship and please to convey the acceptance of the proposal under your excellence of professionalism in your esteemed University. We believe that the carried work as proposed or amended, if need be in future, will definitely contribute value addition in profession and help the scholar practically learning the objectives of study. We also request your good-self to publish the work, if of significance to the profession, in an indexed journal of repute. The work may be extendable for advance studies under your supervision with the same scholar or other if we find the lead for Intellectual Property Rights/ patents, based on the achievement from the current project in the interest of the company.

You are thereby, requested to please advise us the further procedural way in this regard and also if any other services/ support are required from us.

With Regards!

For AIMIL Pharmaceuticals (India) Limited,


(Dr. Anil Kr. Sharma)

Vice President



ourcreativity thinks

ourtechnology awarded by 3 national awards

REGD. OFFICE : 2994/4, Street No. 17, Ranjeet Nagar, New Delhi-110 008, INDIA, **Ph** :+91-11-25701203, 25703041, **Fax** :+91-11-25703064

HEAD OFFICE : 2699, Street No. 13, Ranjeet Nagar, New Delhi-110 008, INDIA, **Ph** :+91-11-25705472, 25703613

MANUFACTURING UNIT-I : A-13/2, Naraina Industrial Area, Phase-I, New Delhi-110 028, INDIA

MANUFACTURING UNIT-II : Saini Majra, Ropar Nalagarh Road, Tehsil Nalagarh, Distt. Solan, (H.P.) -174101, INDIA

Website : www.aimilpharmaceuticals.com **Email**: corporate@aimilpharmaceuticals.com

Ref. No.: AIMIL/PD/2021/35

Date: April 5, 2021

Dr. Showkat R. Mir,
Department of Pharmacognosy & Phytochemistry,
School of Pharmaceutical Education & Research,
Jamia Hamdard, New Delhi 110062

Subject: Our acceptance to sponsor the proposed Consultancy Project entitled " Screening of Herbo-Mineral Formula Boniheal Suspension For Its Bone Health Promoting And Regenerative Activities Using Retinoic Acid Induced Bone Loss Model" under your supervision as Principal Investigator.

Respected Sir,

Greetings of the day!

We refer to our discussions on the subject and subsequent proposal entitled as above, submitted to us for the purpose of sponsorship, I am pleased to convey the acceptance of the proposal. I believe that the work proposed or amended, if need be in future, will definitely contribute to the value addition of the said formulation.

We are ready to continue to support **Ms. Zakiya Usmani** working in your lab for a period of two years to carry out the said research work by providing Rs. 25,000 per month on consolidated basis. The other component of the project funding involve the chemical expenses. I also request your good-self to publish the work in an indexed journal of repute. The work may be extended for advance studies under your supervision with the same scholar or other if we find the lead for Intellectual Property Rights/ patents, based on the achievement from the current project in the interest of the company.

You are thereby, requested to please advise us the further procedural way in this regard and also if any other services/ support are required from us.

Best compliments.

For AIMIL Pharmaceuticals (India) Ltd.


(Dr. Anil Kumar Sharma)

Vice President

*Taking the legacy
of Ayurveda ahead...Scientifically*



More than
36 YEARS OF
HEALTH
CARE

 www.aimilpharmaceuticals.com
 corporate@aimilpharmaceuticals.com
 +91 11 66410000, +91 11 25703613
 2994/4, Street no. 17, Ranjeet Nagar, New Delhi-110008
 Mfg. Unit-I : A-13/2, Naraina Industrial Area, Phase-I,
New Delhi-110028, INDIA
Mfg. Unit-II : Saini Majra, Ropar Nalagarh Road,
Tehsil Nalagarh, Distt. Solan, (H.P.)-174101, INDIA
For any corporate enquiry call : +91-11-66410000

To,
Prof. Farhan Jalees Ahmad
Department of Pharmaceutics
SPER, Jamia Hamdard, New Delhi


Subject: Award of Consulting Project to Prof. Farhan Jalees Ahmad to develop a targeted formulation of GLA and its evaluation.


Dear Prof. Farhan

I am pleased to inform you that our board has decided to award you a consulting project on "Development of a targeted formulation of GLA and its evaluation" as per our discussion regarding development of targeted formulation of GLA under your guidance, please find below details of budget awarded to you for conducting study.

SNO	ACTIVITY	AMOUNT
1)	Fellowship for two selected studentys (Rs 8000 per month for one year) i. Ms Suma Saad ii. Mr Kawish	1.92 lakh
2)	Contingency/Chemicals	1.00 lakh
3)	Travel	0.50 Lakh
4)	Honorarium to PI	1.00 lakh

Please provide details of account for fund transfer
thanks


Dr. Khalid Khan
(Managing Director)
Fermish Clinical Technologies Pvt. Ltd
A-21, Sector-65, Noida, Uttar Pradesh, 201301



Project fund letter

Glenmark

05 Dec 2018

To

Dr. Gaurav K. Jain

(Project Investigator, IBM Study)

CC. Prof. Farhan J. Ahmad (Project Co-Investigator, IBM Study)

Jamia Hamdard

New Delhi 110062


SUB: Approval for Project Titled "Development and Evaluation of Inhaled Beclomethasone Formulation"

Dear Sir,

We, Glenmark Pharmaceuticals Limited, Glenmark House, B. D. Sawant Marg, Chakala, Andheri (E), Mumbai - 400 099, are pleased to offer a Project titled 'Development and Evaluation of Inhaled Beclomethasone Formulation (IBM Study)' to Dr. Gaurav Kumar Jain as Investigator and Prof. Farhan Jalees Ahmad as Co-investigator.



As discussed and approved, the proposed duration of the said project will be maximum of 24 months from the date of CDA/CTA and Glenmark will provide a sum of Rs. 14,560,00/- (Rupees Fourteen Lakhs fifty six thousand Only) as applicable to Investigator. The probable allotment of the fund is attached as discussed.

Thanks in advance for your cooperation, collaboration and interest.


Dr. Krishnaprasad K

General Manager, Glenmark

Glenmark Pharmaceuticals Ltd.
Glenmark House, BD Sawant Marg, Andheri (E), Mumbai 400099, India
(Mail) k.krishna.prasad@glenmarkpharma.com | (Mobile) 9823106811
(Office) 91 22 40828999 | (Extn) 40829083 | CIN No: L24299MH1977P10019582 | www.glenmarkpharma.com

AIMIL

PHARMACEUTICALS (INDIA) LIMITED
MANUFACTURERS & EXPORTERS OF PHARMACEUTICALS PRODUCTS

An ISO 9001: 2008 Certified Company

A 104

Ref. No.: AIMIL/2019/PD/123

Dated: September 09, 2019

To,

Dr. Saima Amin,
Associate Professor,
Department of Pharmaceutics,
School of Pharmaceutical Education & Research,
Jamia Hamdard, New Delhi - 110062

Subject: Our acceptance to sponsor proposed Consultancy Project entitled "DEVELOPMENT OF PHARMACOKINETIC PROFILE OF AMYCORDIAL AND ITS SCREENING FOR ESTROGENIC ACTIVITY" under your supervision as Principal Investigator.

Respected Madam,

Season's Greetings!

We refer to our discussions on the subject and subsequent proposal entitled as above, submitted to us for the purpose of sponsorship and please to convey the acceptance of the proposal under your excellence of professionalism in your esteemed University. We believe that the carried work as proposed or amended, if need be in future, will definitely contribute value addition in profession and help the scholar practically learning the objectives of study. We also request your good-self to publish the work, if of significance to the profession, in an indexed journal of repute. The work may be extendable for advance studies under your supervision with the same scholar or other if we find the lead for Intellectual Property Rights/ patents, based on the achievement from the current project in the interest of the company.

You are thereby, requested to please advise us the further procedural way in this regard and also if any other services/ support are required from us.

With Regards!

For AIMIL Pharmaceuticals (India) Limited,

(Dr. Anil K. Sharma) *Auto 09/09/19*

Vice President



our creativity thinks

our technology awarded by 3 national awards

REGD. OFFICE : 2994/4, Street No. 17, Ranjeet Nagar, New Delhi-110 008, INDIA, Ph :+91-11-25701203, 25703041, Fax :+91-11-25703064
HEAD OFFICE : 2699, Street No. 13, Ranjeet Nagar, New Delhi-110 008, INDIA, Ph :+91-11-25705472, 25703613
MANUFACTURING UNIT-I : A-13/2, Naraina Industrial Area, Phase-I, New Delhi-110 028, INDIA
MANUFACTURING UNIT-II : Saini Majra, Ropar Nalagarh Road, Tehsil Nalagarh, Dist. Solan, (H.P.) -174101, INDIA
Website : www.aimilpharmaceuticals.com Email: corporate@aimilpharmaceuticals.com

OFFICE OF ADVISOR (RESEARCH)
JAMIA HAMDARD, NEW DELHI-110062

No. JH/A(R) /34
Dated: 03/10/2019

Subject: Consultancy Project

A Competent Authority is pleased to approve a proposal of **Dr. Mohan Kamthan**, Department of Biochemistry, SCLS to undertake constancy project from M/S Rajiv Hydraulics Pvt. Ltd., New Delhi. The total estimated cost of project of one year duration is **Rs. 11,20,000/-**. The project will be undertaken with the following conditions.

1. The overhead institutional charges will be 10% of total project cost. PI will not use any portion of overhead institutional charges.
2. The PI consultancy charges of 60,000/- pm to be shared as 30% to Jamia Hamdard and 70% to PI. Income Tax as applicable will be deducted on the PI's share.
3. PI will ensure that there is no conflict of interest and IPR of PI and Jamia Hamdard, if any, will be secured.
4. A copy of final sanction letter will be submit to the Office of Advisor (Research)

This is for needful action by the all concerned.

Raisuddin 3/10/2019
Prof. S. Raisuddin
Advisor (Research)

✓ Dr. Mohan Kamthan, Assistant Professor
Department of Biochemistry, SCLS

Copy to:

5. Dean, School of Chemical and Life Sciences (SCLS)
6. Head, Biochemistry, SCLS
7. Finance Officer
8. PS to VC (for information)
9. PA to PVC for information)
10. Registrar (for information)

JAMIA HAMDARD
(REGISTRAR'S SECRETARIAT)

JH/RO/00/2020/12
Date: 27.02.2020

CIRCULAR

Jamia Hamdard has signed agreement with Sun Pharmaceutical Industries Ltd. (SPIL) for research and academic collaboration in the field of Clinical Pharmacy. One of the components of agreement is related to Ph.D. programme in Pharmaceutical Medicine. For effective operation of the programme the Competent Authority of Jamia Hamdard has approved the following arrangement.

1. ~~Dean, School of Pharmaceutical Education & Research (SPER) will be ex-officio Co-ordinator of the programme. One or two faculty members may be involved for effective management of the programme.~~
2. Jamia Hamdard contact point for the programme will be Advisor (Research).
3. The following Monitoring-cum-Steering Committee has been constituted with a tenure of six years or till the tenure of agreement. The Monitoring-cum-Steering Committee meetings will be convened at least twice in a year. During the meeting six-monthly progress will also be assessed.

Pro Vice Chancellor	-	Chairman
Head, Pharmacology, SPER	-	Member
Head, Pharmacology, HIMSR	-	Member
Member-Secretary, IRB, JH	-	Member
Advisor (Research), JH	-	Member
Dean, SPER	-	Convener

4. The revised fellowship rates will be implemented from April 01, 2020. The existing scholars will continue to draw fellowship at the rates as applicable in the previous agreement. They will be entitled for revised rates w.e.f. April 01, 2020. MTS will be engaged through 'outsourcing' and will be paid accordingly w.e.f. April 01, 2020. After the expiry of total three-year term of the existing research fellows not more than three (03) research fellows will be supported from SPIL grant at a given time. The tenure of fellowship shall be three years.
5. Proper advertisement of the SPIL supported programme will be made about this unique University-Industry collaboration through University Website, Prospectus and other publicity material. In all publications support from the programme will be required to be duly acknowledged.
6. Budget allocation of the received grant is attached. The remainder of grant at the end of each financial year will be treated as 'Institutional Overheads'.

This is for information of all concerned.

Copy to:


1. Dean, SPER
2. Finance Officer
3. Head, Pharmacology, SPER
4. Head, Pharmacology, HIMSR
5. Member-Secretary, IRB, JH
6. Advisor (Research)
7. PS to Vice Chancellor (for information)
8. PA to Pro Vice Chancellor (for information)


(S.S. Akhtar)
Registrar

ACADEMIC COLLABORATION WITH SUN PHARMACEUTICAL INDUSTRIES LIMITED (SPIL) - PROPOSED GRANT ALLOCATION

Item		Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
Fellowship (Research Fellow) (per month)	3	24,000	8,64,000	8,64,000	8,64,000	8,64,000	8,64,000
Consultant remuneration (per month)	1	35,000	4,20,000	4,20,000	4,20,000	4,20,000	4,20,000
Multi Tasking Staff (per month)	1	18,000	2,16,000	2,16,000	2,16,000	2,16,000	2,16,000
Contingency for fellows (annual)	3	25,000	75,000	75,000	75,000	75,000	75,000
Project contingency		50,000	50,000	50,000	50,000	50,000	50,000
Lectures including course work lectures		50,000	50,000	50,000	50,000	50,000	50,000
TA/DA honorarium for members including SRAC members		50,000	50,000	50,000	50,000	50,000	50,000
		17,25,000	17,25,000	17,25,000	17,25,000	17,25,000	17,25,000
Institutional overhead (full to JH)		75,000	75,000	1,65,000	1,65,000	2,59,500	2,59,500
SPIL Grant		18,00,000	18,00,000	18,90,000	18,90,000	19,84,500	19,84,500

Project contingency and contingency to research fellows amount may be merged. Lectures / TA/DA may be reduced by 50% and their remaining 50% may be combined with Project Contingency funds. Accordingly a revised budget may be submitted


 07/02/2020

ACADEMIC COLLABORATION WITH SUN PHARMACEUTICAL INDUSTRIES LIMITED (SPIL) - FUND ALLOCATION (IN RS.)

August 1, 2019 to July 31, 2025

Item	Rate (PM)	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6
Fellowship (Research fellow)	3 24,000** (consolidated)	8,64,000	8,64,000	8,64,000	8,64,000	8,64,000	8,64,000
Remuneration for Consultant	1 35,000*** (consolidated)	4,20,000	4,20,000	4,20,000	4,20,000	4,20,000	4,20,000
Remuneration for Multi-tasking Staff (MTS)	1 18,000** (consolidated)	2,16,000	2,16,000	2,16,000	2,16,000	2,16,000	2,16,000
Research consumables and contingency		1,75,000	1,75,000	2,00,000	2,00,000	2,25,000	2,25,000
Lectures including Ph.D. course work, lectures		25,000	25,000	25,000	25,000	25,000	25,000
TA/DA and honorarium for members including SRAC members		25,000	25,000	25,000	25,000	25,000	25,000
Institutional overhead (full to JH)*		75,000	75,000	1,40,000	1,40,000	2,09,500	2,09,500
SPIL Grant		18,00,000	18,00,000	18,90,000	18,90,000	19,84,500	19,84,500

* Remainder grant will be treated as "Institutional Overhead" and will be fully to JH account.

** The revised fellowship rates will be implemented from April 01, 2020. The existing scholars will continue to draw fellowship at the rates as applicable in the previous agreement. They will be entitled for revised rates w.e.f. April 01, 2020. MTS will be engaged through 'outsourcing' and will be paid accordingly w.e.f. April 01, 2020. After the expiry of total three-year term of the existing research fellows not more than three (03) research fellows will be supported from SPIL grant at a given time. The tenure of fellowship shall be three years.

*** A consultant (serving or retired) will be engaged by search-cum-nomination process. Advisor (Research) will prepare a proposal in this regard.

QUOTATION FOR SERVICES

Quotation No: JH/QTN/19-20/02

Date: 03 June 2019

To


Kind attention: Mr. Sumit Madan
AVP -Product Development Research
Sun Pharmaceutical Industries Ltd.

Ref: Email communications and Letter of Intent

Sub: Quotation for comparative permeation study for nail lacquers.

With reference to the above subject, please find enclosed the best proposal for the services. Assuring you cost effective services with minimum turnaround time and expecting your valuable order at the earliest.

Thanking you



Dr. Zeenat Iqbal
Associate Professor
Dept of Pharmaceutics
Jamia Hamdard



Dr. M Aamir Mirza
Assistant Professor
Dept of Pharmaceutics
Jamia Hamdard

STANDARD TERMS AND CONDITIONS

1. The studies mentioned above will be performed as per mutually agreed protocol with Sponsor;
2. Test, reference products and API to be provided by the sponsor
3. Payment Terms:
 - 50% advance
 - 50% Before Submission of Final Report
4. Mode of Payment- Details of bank transfer has been appended.
5. **Time Schedule:** As per the Study Plan. There may little delay because of scheduled ethical committee meeting.
6. **Total cost of the project:** 100000 (project cost) + 50000 (consultation charges), total 150000 INR. As per the university norms consultation charge should be there, a portion of it goes to the university.
7. Samples can be send to below mentioned address:

Dr. M Aamir Mirza
Dept of Pharmaceutics
School of Pharmaceutical Education and Research
Jamia Hamdard
New Delhi-110062

Mobile- 9213378765

SPONSOR APPROVAL

The price(s) quoted for services listed in this proposal (JH/QTN/19-20/02, dated 03 June 2019) is acceptable to Sun Pharmaceutical Industries Ltd. I have read and agreeing the terms and conditions of this quotation.

For Sun Pharmaceutical Industries Ltd


Authorized signature & seal



JAMIA HAMDARD

(DEEMED TO BE UNIVERSITY)

Accredited by NAAC in 'A' Category

Phone : 011 26059688 (12 Lines)
Fax : 011 26059663
E-mail : inquiry@jamiyahamdard.edu
Website : www.jamiyahamdard.edu

HAMDARD NAGAR
NEW DELHI - 110062

QUOTATION FOR SERVICES

Quotation No: JH/QTN/21-22/01

To

Kind attention: Dr. Sreerama Murty D.V


Managing Trustee
Sree Charitable Trust
Dhanvantri Temple Street
Chintaluru, E.G. Dt


Ref: Telephonic conversations and RFQ (VAN/R&D/148/202)


Sub: Quotation for project entitled "dermal toxicity and anti-psoriatic assays (*in vitro* and *in vivo*) of two Ayurvedic products".

With reference to the above subject, please find enclosed the best proposal for the services. Assuring you cost effective services with minimum turnaround time and expecting your valuable order at the earliest.

Thanking you


15/4
Dr. Zeenat Iqbal
Associate Professor
Dept of Pharmaceutics
Jamia Hamdard


15 APR 2021
Dr. M Aamir Mirza
Assistant Professor
Dept of Pharmaceutics
Jamia Hamdard


HoD, Pharmaceutics

Prof. (Dr.) Yasmin Sultana
Dept of Pharmaceutics
Education & Research
New Delhi-110062

Budgetary details of the project

Total cost = **380,000** INR

It includes the cost of manpower, cost of consumables/excipients/ingredients/plastic ware/glassware, overhead / laboratory development charges and miscellaneous expenses. The quotation doesn't include the cost of cell line.

STANDARD TERMS AND CONDITIONS

1. Payment Terms: The 50% of payment should be made in advanced before start of the project, whereas rest 50% can be paid on submission of draft report. All payments should be done through DD in favour of JAMIA HAMDARD, payable at New Delhi.
2. No Utilization Certificate will be provided for the projects.
3. Jamia Hamdard has TDS exemption certificate, so the sponsor shouldn't deduct it.
4. Mode of Payment- Details of bank transfer has been appended.
5. Time Schedule: The time line of project is 5-6 months, subjected to the approval by IAEC.
6. The cell line is currently not available in all the known labs. Jamia Hamdard's team expects assistance from the sponsor (VAN) also in making the cell lines available. We can also switch to other cell lines after mutual consensus.
7. Samples can be send to below mentioned address:

Dr. M Aamir Mirza
Dept of Pharmaceutics
School of Pharmaceutical Education and Research
Jamia Hamdard
New Delhi-110062

SPONSOR APPROVAL

The price(s) quoted for services listed in this proposal (JH/QTN/21-22/01, 09th April 2021) is acceptable to Sree Charitable Trust, Dhanvantri Temple Street, Chintaluru, E.G.Dt, Andhra Pradesh, India. I have read and agreeing to the terms and conditions of this quotation.

For Sree Charitable Trust

For Sree Charitable Trust



Managing Trustee

Authorized signature & seal

QUOTATION FOR SERVICES

Quotation No: JH/QTN/21-22/03

10th Dec 2021

To

Kind attention: Dr. Sreerama Murty D.V


Managing Trustee
Sree Charitable Trust
Dhanvantri Temple Street
Chintaluru, E.G.Dt

Ref: Telephonic and email communication

Sub: Quotation for project entitled "Evaluation of Anti-Diabetic potential of two Ayurvedic products.

With reference to the above subject, please find enclosed the best proposal for the services. Assuring you cost effective services with minimum turnaround time and expecting your valuable order at the earliest.


Thanking you



Dr. Zeenat Iqbal
Associate Professor
Dept of Pharmaceutics
Jamia Hamdard



Dr. M Aamir Mirza
Assistant Professor
Dept of Pharmaceutics
Jamia Hamdard


HoD, Pharmaceutics
Prof. (Dr.) Yasmin Sultana
Head
Department of Pharmaceutics
SPER, Jamia Hamdard
New Delhi - 110062

Budgetary details of the project

Total cost = 450,000 INR

It includes the cost of manpower, cost of consumables/excipients/ingredients/plastic ware/glassware, overhead / laboratory development charges and miscellaneous expenses.

STANDARD TERMS AND CONDITIONS

1. Payment Terms: The 50% of payment should be made in advanced before start of the project, whereas rest 50% can be paid on submission of draft report. All payments should be done through DD in favour of JAMIA HAMDARD, payable at New Delhi.
2. No Utilization Certificate will be provided for the projects.
3. Jamia Hamdard has TDS exemption certificate, so the sponsor shouldn't deduct it.
4. Mode of Payment- Details of bank transfer has been appended.
5. Time Schedule: The time line of project is 5-6 months, subjected to the approval by IAEC.
6. Samples can be send to below mentioned address:

Dr. M Aamir Mirza
Dept of Pharmaceutics
School of Pharmaceutical Education and Research
Jamia Hamdard
New Delhi-110062

SPONSOR APPROVAL

The price(s) quoted for services listed in this proposal (JH/QTN/21-22/03, 10th Dec 2021) is acceptable to Sree Charitable Trust, Dhanvantri Temple Street, Chintaluru, E.G.Dt, Andhra Pradesh, India. I have read and agreeing to the terms and conditions of this quotation.

For Sree Charitable Trust

D. Sreeval

Authorized signature & seal

For Sree Charitable Trust

Managing Trustee

CONFIDENTIAL DISCLOSURE AGREEMENT

This Confidential Disclosure Agreement (the “Agreement”) is entered into on 03rd day of June, 2019 (the “Effective Date”) by and between **Sun Pharmaceutical Industries Ltd.**, a company incorporated under the laws of India (CIN: L24230GJ1993PLC019050) having its registered office at SPARC, Tandalja, Baroda – 390 020, Gujarat, India and its corporate office at Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400063, India and **Jamia Hamdard**, Mehrauli - Badarpur Rd, Near Batra Hospital, Block D, Hamdard Nagar, New Delhi, Delhi 110062(each, a “Party” and collectively, the “Parties”)

WHEREAS, the Parties are interested in evaluating and discussing a possible business relationship between them relating to possible research arrangement like “Invitro Pearmeation Studies” between them for product/s(the “Transaction”);

WHEREAS, in the course of discussions regarding the Transaction, the Parties may provide each other access to its Confidential Information (as defined below).

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

1. Definitions

1.1. “Affiliate” means any Person who, directly or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with any other Person.

1.2. “Confidential Information” means and includes (a) existence of this Agreement or the information has been requested or made available hereunder;(b) the fact that discussion/negotiation is taking place or have taken place between the Parties concerning the Transaction; (c) any of the terms, conditions or other facts with respect to the Transaction; and (d) all information disclosed by or on behalf of a Party to the other Party during the course of discussion (including without limitation written, oral, visual or electronic disclosures, or samples of ingredients, products or equipment) that relates to such Party’s (or its Affiliates’) research, manufacturing requirements, development activities and programs, or intellectual property, or any information concerning such Party’s (or its Affiliates’) personnel and clients, including but not limited to clinical and non-clinical data, processes, equipment, , product samples and specifications, know-how, trade secrets, technical and non-technical materials. Any Confidential Information disclosed orally or in any other intangible form shall be identified as such and summarized in writing by the Disclosing Party and provided to the Receiving Party within thirty (30) calendar days from the disclosure.

1.3. “Control” means (a) the direct or indirect legal or beneficial ownership of more than fifty percent (50%) of (i) the ownership interests in a Person or (ii) the outstanding voting rights in a Person or (b) the power to otherwise direct the business activities of a Person.

1.4. “Disclosing Party” means the Party that discloses Confidential Information to the other Party.

1.5. “Permitted Recipients” means, with respect to a Party, its Affiliates, and its and their directors, officers, employees, agents, financial institutions and/or third-party consultants (including legal, financial and accounting advisors) and/or contractors.

1.6. “Person” means any individual, corporation, limited liability company, partnership, joint venture, association or other legal entity.

1.7. “Receiving Party” means the Party who receives Confidential Information from the other Party.

2. Treatment of Confidential Information

2.1. Receiving Party shall treat the Confidential Information of the Disclosing Party as confidential and shall safeguard such Confidential Information with the same degree of care with which it holds its own confidential information, but in no event less than reasonable degree of care.

2.2. The Receiving Party shall not, without the prior written consent of the Disclosing Party, (i) disclose to any third party any of the Disclosing Party's Confidential Information, or (ii) use such Confidential Information for any purpose other than in connection with the Transaction.

2.3. The Receiving Party may disclose the Confidential Information to its Permitted Recipients who reasonably need to know such Confidential Information in order to evaluate the Transaction, provided such Permitted Recipients are bound in writing by obligations of confidentiality at least as restrictive as those contained herein. The Receiving Party shall be liable for all the acts and omissions of its Permitted Recipients under this Agreement.

3. Exceptions

3.1. The Receiving Party's obligations under this Agreement regarding the Disclosing Party's Confidential Information shall not apply to the to the extent that the Confidential Information:

- (a) was in the possession of the Receiving Party or any of its Affiliates prior to the time of disclosure as can be reasonably demonstrated by the Receiving Party;
- (b) was or subsequently becomes public knowledge through no fault of the Receiving Party or any of its Affiliates;
- (c) is obtained from a third party who, to Receiving Party's knowledge, is under no obligations of confidentiality with respect to such Confidential Information;
- (d) is independently developed by or for the Receiving Party or any of its Affiliates without violating the terms of this Agreement as can be reasonably demonstrated by the Receiving Party.

3.2. If the Receiving Party or a Permitted Recipient is requested to disclose the Confidential Information of the Disclosing Party (a) in connection with a legal, regulatory or administrative proceeding or otherwise to comply with a requirement under the law or (b) pursuant to an audit or examination by a regulator, bank examiner or self-regulatory organization, the Receiving Party shall, to the extent legally permissible, give the Disclosing Party prompt notice of such request so that the Disclosing Party may seek an appropriate protective order or other remedy, or waive compliance with the relevant provisions of this Agreement. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party, at the Disclosing Party's expense, will reasonably cooperate with and assist the Disclosing Party in such efforts. If the Disclosing Party fails to obtain a protective order or waives compliance with the relevant provisions of this Agreement, the Receiving Party will disclose only that portion of the Confidential Information which it is required to disclose.

4. Term

4.1. This Agreement shall commence on the Effective Date and shall be valid for a period of one(1) year unless terminated earlier by either Party by giving thirty (30) days prior written notice to the other

4.2. Party. Notwithstanding the foregoing, all obligations of confidentiality hereunder of the Receiving Party shall survive for a period of five (5) years from the termination or expiry of this Agreement.

5. Ownership, Warranty & Return

5.1. All Confidential Information disclosed by Disclosing Party to Receiving Party or any of its Permitted Recipients shall be and shall remain the property of the Disclosing Party. Nothing herein shall be construed as granting to the Receiving Party or any of its Permitted Recipients any interest or license under any trade secret, patent, patent application, know-how or any copyright owned or controlled by the Disclosing Party or hereafter granted or filed in which Disclosing Party now has or subsequently obtains any right, title or interest.

5.2. All Confidential Information is provided “*AS IS*” and the Disclosing Party expressly disclaims any warranties, statutory, express or implied, including any warranty of merchantability or fitness for any particular purpose with respect to the Confidential Information.

5.3. Upon the written request of the Disclosing Party, the Receiving Party shall, return (or destroy, at the option and cost of the Disclosing Party) any Confidential Information of Disclosing Party in its possession within thirty (30) business days from such request. Notwithstanding the foregoing, the Receiving Party and its Permitted Recipients (i) may retain one (1) copy of the Disclosing Party’s Confidential Information for archival purpose and in order to comply with its obligations hereunder, and (ii) shall not be required to destroy any computer files to the extent such destruction is not reasonably practical or to the extent it is created by automatic system back up, provided such files are stored securely.

6. General Provisions

6.1. Each Party represents and warrants to the other Party that it has the right to enter into this Agreement and disclose its Confidential Information to the other Party, and that it is not under any obligation to any third party that would prevent it from entering into this Agreement.

6.2. Neither this Agreement, nor either Party’s performance under it, will (a) transfer to the Receiving Party, or create in the Receiving Party, any proprietary right, title, interest or claim in or to any of the Disclosing Party’s Confidential Information; (b) obligate either Party to enter into any other agreement or undertaking of any nature whatsoever with the other Party; or (c) prohibit either Party from entering into any other agreement with any other party, if doing so will not violate such Party’s obligations hereunder.

6.3. The Receiving Party agrees that the disclosure of Confidential Information to any third party in violation of this Agreement may cause irreparable harm to the Disclosing Party, and that any breach or threatened breach of this Agreement by the Receiving Party shall entitle the Disclosing Party to seek injunctive relief and specific performance without proof of actual damages. Such remedy shall not be deemed to be the exclusive remedy for such breach but will be available in addition to any other legal remedies in accordance with applicable law.

6.4. Neither Party shall assign its rights hereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign its rights hereunder to its Affiliates or to the successor of all or substantially all of the business to which this Agreement pertains (whether by sale, merger, acquisition, operation of law or otherwise) without the consent of the other Party. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of its successors and permitted assigns. Any assignment or transfer not in accordance with this Agreement shall be null and void.

6.5. This Agreement shall be governed by and construed in accordance with the laws of the India. Subject to 6.6, the competent courts of Vadodara shall have exclusive jurisdiction over any dispute arising from or in connection to this Agreement.

6.6. Any dispute arising out of or in connection with the terms of this Agreement including any question relating to existence, validity or termination of this Agreement shall be settled in accordance with the Arbitration and Conciliation Act, 1996. The tribunal shall consist of a single arbitrator appointed by mutual consent of both the Parties. The seat of arbitration shall be Vadodara and the language shall be English. In case, Parties fail to mutually appoint the arbitrator within fifteen (15) days of the request by one Party to the other, the Party seeking arbitration shall be free to move to the court of appropriate jurisdiction in Vadodara for appointment of the single arbitrator.

6.7. All notices given hereunder shall be in writing and shall be sent to the Parties hereto at the addresses set forth above or to such other address as a Party may provide.

6.8. If any term of this Agreement or the application thereof shall be deemed invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term of this Agreement shall be valid and enforced to the fullest extent permitted by law.

6.9. This Agreement constitutes the entire agreement between the Parties and supersedes all written or oral prior agreements or understandings with respect to the subject matter hereof. No variation or modification of the terms and provisions of this Agreement shall be valid unless they are provided in writing and signed by authorized representatives of the Parties hereto.


6.10. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

6.11. The Parties are independent contractors, and this Agreement will not establish any relationship of partnership, joint venture, employment, franchise, or agency between the Parties.

6.12. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party acknowledges that an original signature, a copy thereof transmitted by facsimile or by .pdf, or an electronic signature shall constitute an original signature for purposes of this Agreement.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties have caused their duly authorized officers to execute and acknowledge this Agreement as of the date first written above.

Sun Pharmaceutical Industries Limited	Jamia Hamdard
	
Name:	Name: Dr. Zeenat Iqbal
Title:	Title: <i>Dr.</i>
Date:	Date: 03 June 2019



NGO DARPAN UNIQUE ID : AP/2018/0186913
As per income tax act, all donations made
is eligible for tax exemption under section 80(G)



**SREE
CHARITABLE TRUST**

Regd.No. 7 / 2016

3/7, Dhanvantari Temple Street, CHINTALURU - 533 232
Near Rajahmundry, East Godavari District, Andhra Pradesh
e-mail : sreecharitable@chintaluru.com
Mobile : 9440177572

Sree Charitable Trust /R&D/112/2021

DT.02.July 2021

Dr Zeenat Iqbal & Dr Aamir Mirza
Department of Pharmaceutics
School of Pharmaceutical Education and Research
Jamia Hamdard
New Delhi

Sub: Quotation Approval Letter

This letter is with reference to quotation number JH/QTN/21-22/01 and the TDS exemption letter that we received from you on 30 June 2021. We thoroughly verified your quotation and have decided to accept it. As per the quotation, the advance payment of 1, 90,000/- is disbursed. Further, we are also sending the signed agreement form.

Henceforth we request you to make all necessary arrangements (animals, chemicals and standards) for smoothly carrying out the work, particularly *in-vitro* psoriatic cell lines, in all possible ways.

Looking forward to have more collaborative projects in future

With regards

Managing Trustee

Dr Sreerama Murty D.V

Chief Chemist

2/7/2021

K. Gnananath

CONFIDENTIAL DISCLOSURE AGREEMENT

This Confidential Disclosure Agreement (the “Agreement”) is entered into on 03rd day of June, 2019 (the “Effective Date”) by and between **Sun Pharmaceutical Industries Ltd.**, a company incorporated under the laws of India (CIN: L24230GJ1993PLC019050) having its registered office at SPARC, Tandalja, Baroda – 390 020, Gujarat, India and its corporate office at Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400063, India and **Jamia Hamdard**, Mehrauli - Badarpur Rd, Near Batra Hospital, Block D, Hamdard Nagar, New Delhi, Delhi 110062(each, a “Party” and collectively, the “Parties”)

WHEREAS, the Parties are interested in evaluating and discussing a possible business relationship between them relating to possible research arrangement like “Invitro Pearmeation Studies” between them for product/s(the “Transaction”);

WHEREAS, in the course of discussions regarding the Transaction, the Parties may provide each other access to its Confidential Information (as defined below).

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

1. Definitions

1.1. “Affiliate” means any Person who, directly or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with any other Person.

1.2. “Confidential Information” means and includes (a) existence of this Agreement or the information has been requested or made available hereunder;(b) the fact that discussion/negotiation is taking place or have taken place between the Parties concerning the Transaction; (c) any of the terms, conditions or other facts with respect to the Transaction; and (d) all information disclosed by or on behalf of a Party to the other Party during the course of discussion (including without limitation written, oral, visual or electronic disclosures, or samples of ingredients, products or equipment) that relates to such Party’s (or its Affiliates’) research, manufacturing requirements, development activities and programs, or intellectual property, or any information concerning such Party’s (or its Affiliates’) personnel and clients, including but not limited to clinical and non-clinical data, processes, equipment, , product samples and specifications, know-how, trade secrets, technical and non-technical materials. Any Confidential Information disclosed orally or in any other intangible form shall be identified as such and summarized in writing by the Disclosing Party and provided to the Receiving Party within thirty (30) calendar days from the disclosure.

1.3. “Control” means (a) the direct or indirect legal or beneficial ownership of more than fifty percent (50%) of (i) the ownership interests in a Person or (ii) the outstanding voting rights in a Person or (b) the power to otherwise direct the business activities of a Person.

1.4. “Disclosing Party” means the Party that discloses Confidential Information to the other Party.

1.5. “Permitted Recipients” means, with respect to a Party, its Affiliates, and its and their directors, officers, employees, agents, financial institutions and/or third-party consultants (including legal, financial and accounting advisors) and/or contractors.

1.6. “Person” means any individual, corporation, limited liability company, partnership, joint venture, association or other legal entity.

1.7. “Receiving Party” means the Party who receives Confidential Information from the other Party.

2. Treatment of Confidential Information

2.1. Receiving Party shall treat the Confidential Information of the Disclosing Party as confidential and shall safeguard such Confidential Information with the same degree of care with which it holds its own confidential information, but in no event less than reasonable degree of care.

2.2. The Receiving Party shall not, without the prior written consent of the Disclosing Party, (i) disclose to any third party any of the Disclosing Party's Confidential Information, or (ii) use such Confidential Information for any purpose other than in connection with the Transaction.

2.3. The Receiving Party may disclose the Confidential Information to its Permitted Recipients who reasonably need to know such Confidential Information in order to evaluate the Transaction, provided such Permitted Recipients are bound in writing by obligations of confidentiality at least as restrictive as those contained herein. The Receiving Party shall be liable for all the acts and omissions of its Permitted Recipients under this Agreement.

3. Exceptions

3.1. The Receiving Party's obligations under this Agreement regarding the Disclosing Party's Confidential Information shall not apply to the to the extent that the Confidential Information:

- (a) was in the possession of the Receiving Party or any of its Affiliates prior to the time of disclosure as can be reasonably demonstrated by the Receiving Party;
- (b) was or subsequently becomes public knowledge through no fault of the Receiving Party or any of its Affiliates;
- (c) is obtained from a third party who, to Receiving Party's knowledge, is under no obligations of confidentiality with respect to such Confidential Information;
- (d) is independently developed by or for the Receiving Party or any of its Affiliates without violating the terms of this Agreement as can be reasonably demonstrated by the Receiving Party.

3.2. If the Receiving Party or a Permitted Recipient is requested to disclose the Confidential Information of the Disclosing Party (a) in connection with a legal, regulatory or administrative proceeding or otherwise to comply with a requirement under the law or (b) pursuant to an audit or examination by a regulator, bank examiner or self-regulatory organization, the Receiving Party shall, to the extent legally permissible, give the Disclosing Party prompt notice of such request so that the Disclosing Party may seek an appropriate protective order or other remedy, or waive compliance with the relevant provisions of this Agreement. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party, at the Disclosing Party's expense, will reasonably cooperate with and assist the Disclosing Party in such efforts. If the Disclosing Party fails to obtain a protective order or waives compliance with the relevant provisions of this Agreement, the Receiving Party will disclose only that portion of the Confidential Information which it is required to disclose.

4. Term

4.1. This Agreement shall commence on the Effective Date and shall be valid for a period of one(1) year unless terminated earlier by either Party by giving thirty (30) days prior written notice to the other

4.2. Party. Notwithstanding the foregoing, all obligations of confidentiality hereunder of the Receiving Party shall survive for a period of five (5) years from the termination or expiry of this Agreement.

5. Ownership, Warranty & Return

5.1. All Confidential Information disclosed by Disclosing Party to Receiving Party or any of its Permitted Recipients shall be and shall remain the property of the Disclosing Party. Nothing herein shall be construed as granting to the Receiving Party or any of its Permitted Recipients any interest or license under any trade secret, patent, patent application, know-how or any copyright owned or controlled by the Disclosing Party or hereafter granted or filed in which Disclosing Party now has or subsequently obtains any right, title or interest.

5.2. All Confidential Information is provided “*AS IS*” and the Disclosing Party expressly disclaims any warranties, statutory, express or implied, including any warranty of merchantability or fitness for any particular purpose with respect to the Confidential Information.

5.3. Upon the written request of the Disclosing Party, the Receiving Party shall, return (or destroy, at the option and cost of the Disclosing Party) any Confidential Information of Disclosing Party in its possession within thirty (30) business days from such request. Notwithstanding the foregoing, the Receiving Party and its Permitted Recipients (i) may retain one (1) copy of the Disclosing Party’s Confidential Information for archival purpose and in order to comply with its obligations hereunder, and (ii) shall not be required to destroy any computer files to the extent such destruction is not reasonably practical or to the extent it is created by automatic system back up, provided such files are stored securely.

6. General Provisions

6.1. Each Party represents and warrants to the other Party that it has the right to enter into this Agreement and disclose its Confidential Information to the other Party, and that it is not under any obligation to any third party that would prevent it from entering into this Agreement.

6.2. Neither this Agreement, nor either Party’s performance under it, will (a) transfer to the Receiving Party, or create in the Receiving Party, any proprietary right, title, interest or claim in or to any of the Disclosing Party’s Confidential Information; (b) obligate either Party to enter into any other agreement or undertaking of any nature whatsoever with the other Party; or (c) prohibit either Party from entering into any other agreement with any other party, if doing so will not violate such Party’s obligations hereunder.

6.3. The Receiving Party agrees that the disclosure of Confidential Information to any third party in violation of this Agreement may cause irreparable harm to the Disclosing Party, and that any breach or threatened breach of this Agreement by the Receiving Party shall entitle the Disclosing Party to seek injunctive relief and specific performance without proof of actual damages. Such remedy shall not be deemed to be the exclusive remedy for such breach but will be available in addition to any other legal remedies in accordance with applicable law.

6.4. Neither Party shall assign its rights hereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign its rights hereunder to its Affiliates or to the successor of all or substantially all of the business to which this Agreement pertains (whether by sale, merger, acquisition, operation of law or otherwise) without the consent of the other Party. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of its successors and permitted assigns. Any assignment or transfer not in accordance with this Agreement shall be null and void.

6.5. This Agreement shall be governed by and construed in accordance with the laws of the India. Subject to 6.6, the competent courts of Vadodara shall have exclusive jurisdiction over any dispute arising from or in connection to this Agreement.

6.6. Any dispute arising out of or in connection with the terms of this Agreement including any question relating to existence, validity or termination of this Agreement shall be settled in accordance with the Arbitration and Conciliation Act, 1996. The tribunal shall consist of a single arbitrator appointed by mutual consent of both the Parties. The seat of arbitration shall be Vadodara and the language shall be English. In case, Parties fail to mutually appoint the arbitrator within fifteen (15) days of the request by one Party to the other, the Party seeking arbitration shall be free to move to the court of appropriate jurisdiction in Vadodara for appointment of the single arbitrator.

6.7. All notices given hereunder shall be in writing and shall be sent to the Parties hereto at the addresses set forth above or to such other address as a Party may provide.

6.8. If any term of this Agreement or the application thereof shall be deemed invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term of this Agreement shall be valid and enforced to the fullest extent permitted by law.

6.9. This Agreement constitutes the entire agreement between the Parties and supersedes all written or oral prior agreements or understandings with respect to the subject matter hereof. No variation or modification of the terms and provisions of this Agreement shall be valid unless they are provided in writing and signed by authorized representatives of the Parties hereto.


6.10. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

6.11. The Parties are independent contractors, and this Agreement will not establish any relationship of partnership, joint venture, employment, franchise, or agency between the Parties.

6.12. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party acknowledges that an original signature, a copy thereof transmitted by facsimile or by .pdf, or an electronic signature shall constitute an original signature for purposes of this Agreement.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties have caused their duly authorized officers to execute and acknowledge this Agreement as of the date first written above.

Sun Pharmaceutical Industries Limited	Jamia Hamdard
	
Name:	Name: Dr. Zeenat Iqbal
Title:	Title: <i>Dr.</i>
Date:	Date: 03 June 2019

QUOTATION FOR SERVICES

Quotation No: JH/QTN/21-22/03

10th Dec 2021

To

Kind attention: Dr. Sreerama Murty D.V


Managing Trustee
Sree Charitable Trust
Dhanvantri Temple Street
Chintaluru, E.G.Dt

Ref: Telephonic and email communication

Sub: Quotation for project entitled "Evaluation of Anti-Diabetic potential of two Ayurvedic products.

With reference to the above subject, please find enclosed the best proposal for the services. Assuring you cost effective services with minimum turnaround time and expecting your valuable order at the earliest.


Thanking you



Dr. Zeenat Iqbal
Associate Professor
Dept of Pharmaceutics
Jamia Hamdard



Dr. M Aamir Mirza
Assistant Professor
Dept of Pharmaceutics
Jamia Hamdard


HoD, Pharmaceutics
Prof. (Dr.) Yasmin Sultana
Head
Department of Pharmaceutics
SPER, Jamia Hamdard
New Delhi - 110062

Budgetary details of the project

Total cost = 450,000 INR

It includes the cost of manpower, cost of consumables/excipients/ingredients/plastic ware/glassware, overhead / laboratory development charges and miscellaneous expenses.

STANDARD TERMS AND CONDITIONS

1. Payment Terms: The 50% of payment should be made in advanced before start of the project, whereas rest 50% can be paid on submission of draft report. All payments should be done through DD in favour of JAMIA HAMDARD, payable at New Delhi.
2. No Utilization Certificate will be provided for the projects.
3. Jamia Hamdard has TDS exemption certificate, so the sponsor shouldn't deduct it.
4. Mode of Payment- Details of bank transfer has been appended.
5. Time Schedule: The time line of project is 5-6 months, subjected to the approval by IAEC.
6. Samples can be send to below mentioned address:

Dr. M Aamir Mirza
Dept of Pharmaceutics
School of Pharmaceutical Education and Research
Jamia Hamdard
New Delhi-110062

SPONSOR APPROVAL

The price(s) quoted for services listed in this proposal (JH/QTN/21-22/03, 10th Dec 2021) is acceptable to Sree Charitable Trust, Dhanvantri Temple Street, Chintaluru, E.G.Dt, Andhra Pradesh, India. I have read and agreeing to the terms and conditions of this quotation.

For Sree Charitable Trust

D. Sreeval

Authorized signature & seal

For Sree Charitable Trust

Managing Trustee

other party
were discussed.
secretary pdt

R&D

Approved by former R&D UNIT
by Department of Health,
Ministry of Science & Technology,
New Delhi



ESTD: 1925

VENKATESWARA AYURVEDA NILAYAM LTD
Regd. Office: Chintaluru - 533 232, E.G. Dist., A.P. INDIA

VAN/R&D/144/2021
1st March 2021

To
M Aamir Mirza, & Zeenat Iqbal
Department of Pharmaceutis, Faculty of Pharmacy,
Jamia Hamdard,
New Delhi-110062

Sub.: Letter of intent to have collaboration with SPER, Jamia Hamdard

I'm writing on behalf of the M/s. Venkateswara Ayurveda Nilayam LTD. Let me introduce ourselves. We are the pioneers of ayurvedic medicine manufactures with more than ten decades of experience in producing quality-based medicine and the first company in Andhra Pradesh/ Telangana to attain GMP certification. Further, you can visit our website (<https://ayuraarogyam.com/>) for more details.

We have received a DBT project on Psoriasis treatment to our Sree Charitable Trust. Therefore to meet the project objectives, we propose to perform in-vitro/in-vivo psoriatic assays on our developed products. We intend to use your facilities for the same.

We would sincerely appreciate if you can arrange a video conference on zoom platform on Sunday i.e. 7-3-2021 to discuss regarding the facilities available at the institution and know your expertise in the field.

Regards,

For Venkateswara Ayurveda Nilayam Limited
Dr. Sreerama Murty D.V
Managing Director

ISO
9001 : 2015
Certified Company

Over 94 Years of dedication



A First GMP
Certified Company in
Andhra & Telangana

at that
as free

5/3/2024

March 03, 2021

Research Advisor
Amia Hamdard
New Delhi

Dear Sir,

Subject: Appraisal about the LOI offered by an Industry in regard with conduction of a few research studies.

We are happy to apprise to your good office about a LOI which our research group has received in recent past from a very well established organization located in Southern part of India (details and introduction in the attached LOI).

We have had had a few telecons with the concerned authorities at their organization and have apprised them categorically that we could handle the proposed research under the head of a consultancy project wherein adequate funds would be provided by them to meet the requirements of chemicals and other recurring expenses. Besides this an arrangement to pay a fixed stipend (@20000 per month) to the research scholar who would carry out the work has also been proposed. All these payments would be done through the official route as approved by the university.

It gives us an immense pleasure to apprise you further that besides the undersigned we have in our research group Dr. M. Shaharyar (Deptt of Pharm. Chemistry, SPER) and Prof. F J Ahmed (Deptt of Pharmaceutics, SPER) whose participation is proposed to be project/objective specific.

The LOI as shared by the company has been attached. This plea seeks approval/suggestions/instructions required thereof.

Looking forward to an assured support from your kind office.

Submitted please

Kindest Regards,

Zeenat Iqbal

Dr. Zeenat Iqbal
(Senior Research Consultant)

Aamir Mirza

Dr. M. Aamir Mirza
(Research Consultant)

12-32021
02

As advised by the other party (M/s Venkateswara Ayurveda Nilayam Ltd.), please the video conference and then submit a detail project with:

1. Role and responsibility and work - package of all participants.
2. Financial component
3. Time line

Dr. Zeenat Iqbal
SPER

R = 11
5/3/2024

PTC

Prof. Raisuddin, Research Advisor

Following is submitted for your kind perusal please

1. A video conference was requested by the other party was conducted and the project finances were discussed. The product (patented for studies) is a proprietary ppt to be tested for antipersonatic action. Our team has enough expertise to carry out the proposed objectives and this was communicated to the other party. Consequently, the following (as solicited by your good office) were crystallised out:

(1) Role of Responsibility and work package of all participants

* Dr. Leerat Jhal : Sr. member of the team, responsible for devising strategies as per the TPP envisaged for the specific applicable guidelines; governing resources; applicant for IAEA approvals; has an experience of dealing with similar studies.

* Dr. Aamir Moez : Point person for routine communication with the other party; close monitoring of the lab. activities and would be the signatory for all financial transactions as per the university protocols.

* Dr. M. Chaturvedi : Intellectual inputs in interpretation of data, final report preparation and drafting of I.P.# material generated thereof.

* Prof. Farhan J. Ahmad : Intellectual inputs may be sought if need be as he has proficient past industrial experience.

Quality Target Product Profile # Intellectual Property

(2) Financial Component - Proposed cost is INR 4,10,000/-

(3) Time-line - 5 to 6 months, subjected to the approval by IAEA

P.S: None of the consultants (investigators) will claim any remuneration. INR 20,000 per month is however proposed as a stipend for the research scholar (bench worker)

Submitted Lead 21/12/2021

Dated: 9.7.2021

Subject: Industry/Consultancy Project reg.

Dr. Zeenat Iqbal (SPER) and Dr. M. Amir Mirza (SPER) have proposed to undertake a consultancy project from M/s Venkateswara Ayurveda Nilayam Ltd, Chintaluru, A.P. They have submitted clarification with regard to roles, responsibilities and financial components.

It is proposed that approval may please be granted for the above faculty members to undertake the consultancy project and submitted the same to the office of Advisor (Research). They will be advised to obtain final sanction letter from the industry and also to take approval of Ethics Committee in case applicable.

Submitted for kind approval, please.

R. Raisuddin
09/07/21
Prof. S. Raisuddin
Advisor, Research

Vice Chancellor

Approved
Dr. A. Khan
9.7.21

Advisor

May kindly see approval of the Vice Chancellor for your consultancy project proposal.

Please proceed ahead as follows:

1. An MOU may be signed between the company & JH. (Please contact legal cell.). A copy of MOU may be provided to us.
2. Sharing of consultancy charges will be as per JH norms in this regard.
3. Please keep updated IQAC/Advisor (Domestic) office about completion of project for NIAF/NAAC documentation.

For useful.

A Zeenat Iqbal
SPER

R. Raisuddin
13/07/21



Thanks for the grant of approval. Trust that we may proceed with the execution as per the earlier submissions.

The responses for the aforementioned points are as under:

1. The project has been solicited as per the earlier project model (quite similar to EMR). As ^{per} discussions with your good office we did not require any MoU. If later we may enter into a bigger collaboration, we shall like to have a proper MoU.
2. We are not charging any personal fees and have requested to grant us funds for hiring a Research Scholar for 4 to 5 months. The remaining amount shall be used for chemicals/kits etc. The final negotiated amount stands at INR 3.80 lacs. An amount of INR 20,000 shall be withdrawn to pay the hired scholar. (All these submissions are mentioned in the prepages)
3. The IQAC / Advisor Research offices shall be duly apprised about the commencement as well as successful completion of the said project.

Zeena P
(DR. ZEENAT IQBAL)
SPER

Prof. Raisuddin
Advisor, Research



NGO DARPAN UNIQUE ID : AP/2018/0186913
As per income tax act, all donations made
is eligible for tax exemption under section 80(G)



**SREE
CHARITABLE TRUST**

Regd.No. 7 / 2016

3/7, Dhanvantari Temple Street, CHINTALURU - 533 232
Near Rajahmundry, East Godavari District, Andhra Pradesh
e-mail : sreecharitable@chintaluru.com
Mobile : 9440177572

Sree Charitable Trust /R&D/112/2021

DT.02.July 2021

Dr Zeenat Iqbal & Dr Aamir Mirza
Department of Pharmaceutics
School of Pharmaceutical Education and Research
Jamia Hamdard
New Delhi

Sub: Quotation Approval Letter

This letter is with reference to quotation number JH/QTN/21-22/01 and the TDS exemption letter that we received from you on 30 June 2021. We thoroughly verified your quotation and have decided to accept it. As per the quotation, the advance payment of 1, 90,000/- is disbursed. Further, we are also sending the signed agreement form.

Henceforth we request you to make all necessary arrangements (animals, chemicals and standards) for smoothly carrying out the work, particularly *in-vitro* psoriatic cell lines, in all possible ways.

Looking forward to have more collaborative projects in future

With regards

Managing Trustee

Dr Sreerama Murty D.V

Chief Chemist

2/7/2021

K. Gnananath

CONFIDENTIAL DISCLOSURE AGREEMENT

This Confidential Disclosure Agreement (the “Agreement”) is entered into on 03rd day of June, 2019 (the “Effective Date”) by and between **Sun Pharmaceutical Industries Ltd.**, a company incorporated under the laws of India (CIN: L24230GJ1993PLC019050) having its registered office at SPARC, Tandalja, Baroda – 390 020, Gujarat, India and its corporate office at Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai – 400063, India and **Jamia Hamdard**, Mehrauli - Badarpur Rd, Near Batra Hospital, Block D, Hamdard Nagar, New Delhi, Delhi 110062(each, a “Party” and collectively, the “Parties”)

WHEREAS, the Parties are interested in evaluating and discussing a possible business relationship between them relating to possible research arrangement like “Invitro Pearmeation Studies” between them for product/s(the “Transaction”);

WHEREAS, in the course of discussions regarding the Transaction, the Parties may provide each other access to its Confidential Information (as defined below).

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows:

1. Definitions

1.1. “Affiliate” means any Person who, directly or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with any other Person.

1.2. “Confidential Information” means and includes (a) existence of this Agreement or the information has been requested or made available hereunder;(b) the fact that discussion/negotiation is taking place or have taken place between the Parties concerning the Transaction; (c) any of the terms, conditions or other facts with respect to the Transaction; and (d) all information disclosed by or on behalf of a Party to the other Party during the course of discussion (including without limitation written, oral, visual or electronic disclosures, or samples of ingredients, products or equipment) that relates to such Party’s (or its Affiliates’) research, manufacturing requirements, development activities and programs, or intellectual property, or any information concerning such Party’s (or its Affiliates’) personnel and clients, including but not limited to clinical and non-clinical data, processes, equipment, , product samples and specifications, know-how, trade secrets, technical and non-technical materials.Any Confidential Information disclosed orally or in any other intangible form shall be identified as such and summarized in writing by the Disclosing Party and provided to the Receiving Party within thirty (30) calendar days from the disclosure.

1.3. “Control” means (a) the direct or indirect legal or beneficial ownership of more than fifty percent (50%) of (i) the ownership interests in a Person or (ii) the outstanding voting rights in a Person or (b) the power to otherwise direct the business activities of a Person.

1.4. “Disclosing Party” means the Party that discloses Confidential Information to the other Party.

1.5. “Permitted Recipients” means, with respect to a Party, its Affiliates, and its and their directors, officers, employees, agents, financial institutions and/or third-party consultants (including legal, financial and accounting advisors) and/or contractors.

1.6. “Person” means any individual, corporation, limited liability company, partnership, joint venture, association or other legal entity.

1.7. “Receiving Party” means the Party who receives Confidential Information from the other Party.

2. Treatment of Confidential Information

2.1. Receiving Party shall treat the Confidential Information of the Disclosing Party as confidential and shall safeguard such Confidential Information with the same degree of care with which it holds its own confidential information, but in no event less than reasonable degree of care.

2.2. The Receiving Party shall not, without the prior written consent of the Disclosing Party, (i) disclose to any third party any of the Disclosing Party's Confidential Information, or (ii) use such Confidential Information for any purpose other than in connection with the Transaction.

2.3. The Receiving Party may disclose the Confidential Information to its Permitted Recipients who reasonably need to know such Confidential Information in order to evaluate the Transaction, provided such Permitted Recipients are bound in writing by obligations of confidentiality at least as restrictive as those contained herein. The Receiving Party shall be liable for all the acts and omissions of its Permitted Recipients under this Agreement.

3. Exceptions

3.1. The Receiving Party's obligations under this Agreement regarding the Disclosing Party's Confidential Information shall not apply to the to the extent that the Confidential Information:

- (a) was in the possession of the Receiving Party or any of its Affiliates prior to the time of disclosure as can be reasonably demonstrated by the Receiving Party;
- (b) was or subsequently becomes public knowledge through no fault of the Receiving Party or any of its Affiliates;
- (c) is obtained from a third party who, to Receiving Party's knowledge, is under no obligations of confidentiality with respect to such Confidential Information;
- (d) is independently developed by or for the Receiving Party or any of its Affiliates without violating the terms of this Agreement as can be reasonably demonstrated by the Receiving Party.

3.2. If the Receiving Party or a Permitted Recipient is requested to disclose the Confidential Information of the Disclosing Party (a) in connection with a legal, regulatory or administrative proceeding or otherwise to comply with a requirement under the law or (b) pursuant to an audit or examination by a regulator, bank examiner or self-regulatory organization, the Receiving Party shall, to the extent legally permissible, give the Disclosing Party prompt notice of such request so that the Disclosing Party may seek an appropriate protective order or other remedy, or waive compliance with the relevant provisions of this Agreement. If the Disclosing Party seeks a protective order or other remedy, the Receiving Party, at the Disclosing Party's expense, will reasonably cooperate with and assist the Disclosing Party in such efforts. If the Disclosing Party fails to obtain a protective order or waives compliance with the relevant provisions of this Agreement, the Receiving Party will disclose only that portion of the Confidential Information which it is required to disclose.

4. Term

4.1. This Agreement shall commence on the Effective Date and shall be valid for a period of one(1) year unless terminated earlier by either Party by giving thirty (30) days prior written notice to the other

4.2. Party. Notwithstanding the foregoing, all obligations of confidentiality hereunder of the Receiving Party shall survive for a period of five (5) years from the termination or expiry of this Agreement.

5. Ownership, Warranty & Return

5.1. All Confidential Information disclosed by Disclosing Party to Receiving Party or any of its Permitted Recipients shall be and shall remain the property of the Disclosing Party. Nothing herein shall be construed as granting to the Receiving Party or any of its Permitted Recipients any interest or license under any trade secret, patent, patent application, know-how or any copyright owned or controlled by the Disclosing Party or hereafter granted or filed in which Disclosing Party now has or subsequently obtains any right, title or interest.

5.2. All Confidential Information is provided “*AS IS*” and the Disclosing Party expressly disclaims any warranties, statutory, express or implied, including any warranty of merchantability or fitness for any particular purpose with respect to the Confidential Information.

5.3. Upon the written request of the Disclosing Party, the Receiving Party shall, return (or destroy, at the option and cost of the Disclosing Party) any Confidential Information of Disclosing Party in its possession within thirty (30) business days from such request. Notwithstanding the foregoing, the Receiving Party and its Permitted Recipients (i) may retain one (1) copy of the Disclosing Party’s Confidential Information for archival purpose and in order to comply with its obligations hereunder, and (ii) shall not be required to destroy any computer files to the extent such destruction is not reasonably practical or to the extent it is created by automatic system back up, provided such files are stored securely.

6. General Provisions

6.1. Each Party represents and warrants to the other Party that it has the right to enter into this Agreement and disclose its Confidential Information to the other Party, and that it is not under any obligation to any third party that would prevent it from entering into this Agreement.

6.2. Neither this Agreement, nor either Party’s performance under it, will (a) transfer to the Receiving Party, or create in the Receiving Party, any proprietary right, title, interest or claim in or to any of the Disclosing Party’s Confidential Information; (b) obligate either Party to enter into any other agreement or undertaking of any nature whatsoever with the other Party; or (c) prohibit either Party from entering into any other agreement with any other party, if doing so will not violate such Party’s obligations hereunder.

6.3. The Receiving Party agrees that the disclosure of Confidential Information to any third party in violation of this Agreement may cause irreparable harm to the Disclosing Party, and that any breach or threatened breach of this Agreement by the Receiving Party shall entitle the Disclosing Party to seek injunctive relief and specific performance without proof of actual damages. Such remedy shall not be deemed to be the exclusive remedy for such breach but will be available in addition to any other legal remedies in accordance with applicable law.

6.4. Neither Party shall assign its rights hereunder without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign its rights hereunder to its Affiliates or to the successor of all or substantially all of the business to which this Agreement pertains (whether by sale, merger, acquisition, operation of law or otherwise) without the consent of the other Party. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of its successors and permitted assigns. Any assignment or transfer not in accordance with this Agreement shall be null and void.

6.5. This Agreement shall be governed by and construed in accordance with the laws of the India. Subject to 6.6, the competent courts of Vadodara shall have exclusive jurisdiction over any dispute arising from or in connection to this Agreement.

6.6. Any dispute arising out of or in connection with the terms of this Agreement including any question relating to existence, validity or termination of this Agreement shall be settled in accordance with the Arbitration and Conciliation Act, 1996. The tribunal shall consist of a single arbitrator appointed by mutual consent of both the Parties. The seat of arbitration shall be Vadodara and the language shall be English. In case, Parties fail to mutually appoint the arbitrator within fifteen (15) days of the request by one Party to the other, the Party seeking arbitration shall be free to move to the court of appropriate jurisdiction in Vadodara for appointment of the single arbitrator.

6.7. All notices given hereunder shall be in writing and shall be sent to the Parties hereto at the addresses set forth above or to such other address as a Party may provide.

6.8. If any term of this Agreement or the application thereof shall be deemed invalid or unenforceable, the remainder of this Agreement shall be unaffected thereby and each remaining term of this Agreement shall be valid and enforced to the fullest extent permitted by law.

6.9. This Agreement constitutes the entire agreement between the Parties and supersedes all written or oral prior agreements or understandings with respect to the subject matter hereof. No variation or modification of the terms and provisions of this Agreement shall be valid unless they are provided in writing and signed by authorized representatives of the Parties hereto.


6.10. No waiver by any Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the Party so waiving. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.


6.11. The Parties are independent contractors, and this Agreement will not establish any relationship of partnership, joint venture, employment, franchise, or agency between the Parties.

6.12. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed an original, but all of which together shall constitute one and the same instrument. Each Party acknowledges that an original signature, a copy thereof transmitted by facsimile or by .pdf, or an electronic signature shall constitute an original signature for purposes of this Agreement.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties have caused their duly authorized officers to execute and acknowledge this Agreement as of the date first written above.

Sun Pharmaceutical Industries Limited	Jamia Hamdard
	
Name:	Name: Dr. Zeenat Iqbal
Title:	Title: <i>Dr.</i>
Date:	Date: 03 June 2019



Hydrogreen Leaf Private Limited

(CIN : U74999UP2020PTC132515)

14th January, 2021

To

The Registrar

Jamia Hamdard

New Delhi 110062

The budget provision for the R&D work on Cannabis Species to be under taken in the Centre for Transgenic Plant Development, Dept. of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062 under the supervision of Prof. M.Z. Abdin (PI) has been sanctioned as per the details mentioned below :

BUDGET

Non- Recurring- Instruments

S.No.	Name of the Instruments	Cost in Rupees	Remarks
1	- 80°C Deep Freezer	10,00,000	For Sample storage
2	Advanced HPLC System	40,00,000	For Sample analysis
3	Millipore Purification System 5L	10,00,000	For making media
4	Super Critical CO ₂ Extractor, 2L	60,00,000	For extraction of phytochemicals
Total (A)		1,20,00,000	

Recurring - Manpower

S.No.	Name of the Post	No. of Post	Salary per month	Per Annum	For 3 Years
1	Post Doc Fellow	01	55,000	6,60,000	19,80,000
2	Project Associate-I	02	31,000 + HRA (30%)	80,600 x 2 = 9,67,200	29,01,600
3	Technical Assistant	01	20,000 +HRA (30%) x 2	26,000 = 3,12,000	9,36,000
Total (B)				19,39,200	58,17,600


(S. U. Zafar)



Hydrogreen Leaf Private Limited

(CIN : U74999UP2020PTC132515)

Recurring - Consumables

S.No.	Name of the Head	Amount per year	For 3 Years
1	Contingency *	2,00,000	6,00,000
2	Chemical and Consumables	20,00,000	60,00,000
3	Maintenance of Equipments	5,00,000	15,00,000
4	Travel	2,00,000	6,00,000
Total (C)		29,00,000	87,00,000
Grand Total (B+C)			1,45,17,600
5	Resource cost of Jamia Hamdard (Over Head) 10% of Recurring Budget	4,83,920	14,51,760
6	Consultancy Fee 10% of Recurring Budget	4,83,920	14,51,760
Total (D)		9,67,840	29,03,520
Grand Total (B+C+D)			1,74,21,120
Total Cost of the Project (A+B+C+D)			2,94,21,120

*The Contingency grant will be used for unforeseen expenditure and also for **Secretarial Assistant**


Total for First Year Budget (Recurring + Non-Recurring) = Rs. 58,07,840 + 1,20,00,000 = Rs.1,78,07,040

Total for Second Year Budget (Recurring) = Rs. 58,07,840

**Total for Third Year Budget (Recurring) = Rs. 58,07,840

(**This figure may change based on the revision by Govt. funding agencies)

The funds for the First Year of the project will be released in April, 2021 for the Financial Year 2021-2022.


Sd/-
(S.U.ZAFAR)
Director

Hydrogreen Leaf Pvt.Ltd.

REGISTRATION FORM
POST SEMINAR ONE DAY WORKSHOP

on

GCMS METABOLOMICS

Name (Dr./Mr./Mrs./Miss.): _____

Qualification: _____

Address: _____

E-mail: _____

Phone No.: _____ Mobile: _____

Registration Fee: @200/ candidate, cash/cheque in favor of Jamia Hamdard

Amount paid: _____ Option cash/ DD. No: _____

Date: _____

Bank: _____

(Registration limited to 50 only)

Signature of Applicant

FOR REGISTRATION: Contact Ms Varisha Anjum (9891576951), Sheeraz Ahmad (9953162001)

Program Schedule:

Lecture 1: Basics of GCMS by Indrajeet Sen (Agilent technologies) 11:0 – 12.0 am

Lecture 2: Metabolomic workflow using GCMS and LCMS by Saurabh Nagpal (Agilent technologies) 12:0 – 1.0 pm

Demo: GCMS analysis of metabolites by Indrajeet Sen & Saurabh Nagpal (Agilent technologies) 2:0– 5:0 pm

CO-ORDINATORS

Dr Sayeed Ahmad, Dr SR Mir ✓

Department of Pharmacognosy and Phytochemistry,

School of Pharmaceutical Education and Research, Jamia Hammdard,

New Delhi-110062

Agilent Technologies

POST SEMINAR ONE DAY WORKSHOP

on

GCMS METABOLOMICS

17TH MAY 2017



Organized By

Department of Pharmacognosy and Phytochemistry,
SCHOOL OF PHARMACEUTICAL EDUCATION AND RESEARCH,
JAMIA HAMDARD, Hamdard Nagar, New Delhi-110062

PROGRAM SPONSOR: AGILENT TECHNOLOGIES

Workshop on Chromatographic Solutions

The Science and Practice of HPLC



Organized By

Department of Pharmacognosy & Phytochemistry
School of Pharmaceutical Education & Research
Jamia Hamdard

In Association With

Society of Pharmaceutical Education & Research


On The Occasion of

WORLD PHARMACIST DAY
25th September, 2019

High Performance Liquid Chromatograph

Prominence

 **SHIMADZU**
Excellence in Science



SPEAKERS | DEMONSTRATORS

Dr. Arshad Khuroo
(Sun Pharmaceutical Industries, Gurgaon)

Mr. Sachin Gangwar
(Application Executive, Spinco Biotech)

Dr. Santosh Bhardwaj
(Deputy Manager Application Shimadzu)

Dr. Puneet
(Senior Application Scientist, Spinco Biotech)

Mr. Bipendra Singh
(Product manager, LCMS)

ORGANISERS | SPONSORS

School of Pharmaceutical Education and Research, Jamia Hamdard

Shimadzu Corporation
M/s Spinco Biotech Private India Limited, India

Society of Pharmaceutical Education & Research (Delhi Chapter)

Highlights of Workshop

- ✧ The main objective is to acquaint prospective users to the working of HPLC.
- ✧ The workshop is designed to offer the conceptual learning and hands-on training to the participants.
- ✧ The deliberations would cover topics of method development and applications of HPLC.
- ✧ Application notes and relevant study material will be shared.
- ✧ Shimadzu's flagship product *i-series* HPLC will be on display.

Call : 9811385772 | Email: prljamia.sper@gmail.com

REGISTRATION FEE

- Teachers and Scholars : Rs 500/-
- Industry : Rs 1000/-

THINGS TO REMEMBER

- Date of Workshop : 25th September 2019
- Number of Participants : 100 only

Workshop Secretariat
Phytopharmaceutical Research Lab.
School of Pharmaceutical Education and Research (SPER)
Jamia Hamdard, New Delhi-110 062



**Workshop on Chromatographic Solutions
The Science and Practice of HPLC**



**Organized By
Department of Pharmacognosy & Phytochemistry
School of Pharmaceutical Education & Research
Jamia Hamdard
In Association With
Society of Pharmaceutical Education & Research
On The Occasion of
WORLD PHARMACIST DAY
25th September, 2019**

REGISTRATION FEE

Industry Rs 1000/- Teachers and Scholars Rs 500/-

REGISTRATION DETAILS

Name (Dr. / Mr./ Ms.)

Organization

Designation.....

Address

.....

State..... Pin Code

Mobile No.....

E-mail.....

Are you a member of Society of Pharmaceutical Education and Research? Y/N

If yes;

Registered with branch

Membership No. Valid up to

- Registration fee includes registration kit and hospitality.**
- Last date of registration form submission is 20thSeptember, 2019**
- Limited seats are available for registration.**

PAYMENT MODE

- Cash
- Draft - Bank.....
Draft No.....
Dated.....

Please send draft in favour of "Jamia Hamdard, New Delhi"
Address: Phytopharmaceutical Research Lab.
Department of Pharmacognosy and Phytochemistry
School of Pharmaceutical Education and Research
Jamia Hamdard, New Delhi 110062

Contact details: 9811385772 Email: prljamia.sper@gmail.com

Webinar on Preparative Purification Solutions held online on 3/6/2021

A webinar on Preparative Purification Solutions was held on 3/6/2022 virtually. The event was attended by about 100 participants. The event was sponsored by Shimadzu.

School of Pharmaceutical Education and Research
JAMIA HAMDARD
(Deemed University)



Invite you to the webinar on
SHIMADZU PREPARATIVE-PURIFICATION SOLUTION

ORGANISERS

 <p>Prof. (Dr.) Mohd Amir Ex-Dean , SPER JAMIA HAMDARD</p>	 <p>Prof. Vidhu Aeri Dean, SPER JAMIA HAMDARD</p>	 <p>Dr. Showkat R. Mir SPER, JAMIA HAMDARD</p>
--	---	--

Speaker: J. Sakti Saravanan

COORDINATORS
Mr. Rahul Dev Sharma
Mr Gaurav Kumar
SPINCO BIOTECH



June
03

Thursday June 03, 2021
Time: 11.00-12.00 p.m.

Click here to
REGISTER NOW >



SPONSORED BYFor further information, please write to gaurav.kumar@spincotech.com